After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
BMY belongs to the Healthcare sector of the NYSE while operating in the Drug Manufacturers – General industry. The current market capitalization of Bristol-Myers Squibb Co. is $109.66B. A total of 13.51 million shares were traded on the day, compared to an average of 16.72M shares.
In the most recent transaction, BOERNER CHRISTOPHER S. bought 2,000 shares of BMY for 49.78 per share on Dec 05 ’23. After the transaction, the Chief Executive Officer now owns 82,672 company shares. In a previous transaction on Nov 28 ’23, BOERNER CHRISTOPHER S. bought 3,071 shares at 48.86 per share. BMY shares that Chief Executive Officer owns now total 79,384.
Among the insiders who bought shares, Samuels Theodore R. II acquired of 8,500 shares on Nov 20 ’23 at a per-share price of $49.81. This resulted in the Director holding 35,500 shares of BMY after the transaction. In another insider transaction, Powell Ann sold 17,986 shares at $61.25 per share on Aug 24 ’23. Company shares held by the EVP, Chief Human Resources now total 27,868.
Dividend
Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Bristol-Myers Squibb Co. pays an annual dividend of $2.31, resulting in a dividend yield of 4.26%, and it has a price to earnings (P/E) ratio of 14.06. BMY’s most recent ex-dividend date was 4/4/2024 when it declared a $0.60 quarterly dividend that was paid in cash on 5/1/2024. Previously, the company paid the dividend on 2/1/2024 with an ex-dividend date of 1/4/2024. The BMY stock dividend was $0.60 per share in cash.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BMY has a high of $71.07 and a low of $47.58.
As of this writing, BMY has an earnings estimate of $1.58 per share for the current quarter. EPS was calculated based on a consensus of 16 estimates, with a high estimate of $1.94 per share and a lower estimate of $1.3. The company reported an EPS of $1.82 in the last quarter, which was 13.00% higher than expectations of $1.61.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BMY’s latest balance sheet shows that the firm has $17.22B in Cash & Short Term Investments as of fiscal 2021. There were $45.60B in debt and $21.87B in liabilities at the time. Its Book Value Per Share was $14.56, while its Total Shareholder’s Equity was $36.01B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BMY is Buy with a score of 3.27.
